Inventiva S.A. files 20-F

Inventiva S.A., a clinical-stage biopharmaceutical company, reported a net loss of €354.1 million for the year ended December 31, 2025, significantly wider than the €184.2 million loss in 2024. The company's financial position indicates a material uncertainty regarding its ability to continue as a going concern, with current cash and cash equivalents insufficient to cover operating needs for at least the next 12 months.